Lantheus buys rights to PET oncology imaging agent
Lantheus Medical Imaging parent company Lantheus Holdings said it has purchase...Read more on AuntMinnie.comRelated Reading:
Lantheus experiences net loss in Q4, full fiscal year
Lantheus touts ASCO GU talks with PSMA agent
Lantheus submits drug master file for imaging biomarker
Point Biopharma to use Lantheus' PyL in clinical trial
Lantheus divests Puerto Rico nuclear medicine businesses (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 30, 2021 Category: Radiology Source Type: news
Dutch look for answers to fix nuclear medicine training
Is there a way to stem the declining numbers of residents pursuing specialtie...Read more on AuntMinnie.comRelated Reading:
Survey finds many radiologists still fear being replaced by AI
SNMMI 2020: Medical students key to the specialty's future
ABNM, ABR scrap plan to revamp nuclear medicine training
Proposal would dissolve ABNM, fold functions into ABR
Nuclear medicine residents see 'dismal' job market (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 26, 2021 Category: Radiology Source Type: news
New treatment proves more effective and less toxic for neuroendocrine tumor patients
(Society of Nuclear Medicine and Molecular Imaging) A new treatment for late-stage neuroendocrine tumors (NETs) has been found to be more effective and have fewer side effects than the current standard of care, according to research published in the March issue of The Journal of Nuclear Medicine. The novel peptide receptor radionuclide therapy holds promise to reduce mortality among NET patients and decrease the financial burden of their continual treatment. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 22, 2021 Category: Cancer & Oncology Source Type: news
Immuno-PET can give physicians early insight into tumor response to targeted therapy
(Society of Nuclear Medicine and Molecular Imaging) Immuno-positron emission tomography (PET) imaging can provide early insight into a tumor's response to targeted therapy, allowing physicians to select the most effective treatment for patients who have cancer. The new research was published in the March issue of The Journal of Nuclear Medicine. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 12, 2021 Category: International Medicine & Public Health Source Type: news
BWXT, GMS form joint venture for Asia-Pacific
BWX Technologies (BWXT) subsidiary and medical isotope and radiopharmaceutica...Read more on AuntMinnie.comRelated Reading:
BWXT appoints new president for BWXT ITG Canada
FDA approves BWXT's radiopharmaceutical
BWXT completes acquisition of Nordion business
BWXT selects Mo-99 irradiation provider
GMS to divest Chinese nuclear medicine business (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 9, 2021 Category: Radiology Source Type: news
NorthStar, IBA expand Tc-99m collaboration
NorthStar Medical Radioisotopes and proton therapy developer Ion Beam Application...Read more on AuntMinnie.comRelated Reading:
NorthStar reorganizes to advance nuclear medicine agents
IBA adds CBCT to 2 proton therapy centers
NorthStar promotes Estrum to executive vice president
IBA receives 1st payment from Chinese licensing deal
IBA secures large proton therapy contract in China
NorthStar, Monopar team up to create COVID-19 therapies (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 8, 2021 Category: Radiology Source Type: news
Nuclear medicine
(Source: ScienceNOW)
Source: ScienceNOW - March 4, 2021 Category: Science Authors: Normile, D. Tags: Asia/Pacific News, Medicine, Diseases, Scientific Community Feature Source Type: news
Who Gets Pott ’ s Puffy Tumor?
Discussion
Pott’s puffy tumor (PPT) was first described by Sir Percivall Pott in 1775 and who also described other orthopaedic and oncological diseases subsequently named for him. “It is a subperiosteal abscess of the anterior wall of the frontal sinus associated with underlying frontal osteomyelitis.” The tender edema and swelling of the forehead is the sign of PPT. Associated fever, headache, and rhinorrhea along with similar problems such as postnasal drip or nasal congestion are common. Associated ophthalmological problems include peri-orbital or eyelid edema and/or preseptal cellulitis. Ptosis and di...
Source: PediatricEducation.org - March 1, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Lantheus experiences net loss in Q4, full fiscal year
A slight increase in revenue for the fourth quarter wasn't enough to offse...Read more on AuntMinnie.comRelated Reading:
Lantheus touts ASCO GU talks with PSMA agent
Lantheus submits drug master file for imaging biomarker
Point Biopharma to use Lantheus' PyL in clinical trial
Lantheus divests Puerto Rico nuclear medicine businesses
FDA clears Lantheus' AI bone software (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 27, 2021 Category: Radiology Source Type: news
SNMMI confirms Medicare reimbursement error for Cerianna
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) said that th...Read more on AuntMinnie.comRelated Reading:
SNMMI, Zionexa call out CMS for reimbursement error
SNMMI to hold 2021 annual meeting virtually
SNMMI urges fast-track review of Technegas for V/Q scans
SNMMI: Imagers should get COVID-19 shots early
Imaging agent for breast cancer PET gets FDA nod (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 24, 2021 Category: Radiology Source Type: news
Molecular imaging determines effectiveness of novel metastatic breast cancer treatment
(Society of Nuclear Medicine and Molecular Imaging) Molecular imaging can successfully predict response to a novel treatment for ER-positive, HER2-negative metastatic breast cancer patients who are resistant to hormonal therapy. According to research published in the February issue of The Journal of Nuclear Medicine, positron emission tomography (PET) imaging using an imaging agent called 18F-fluoroestradiol can help to determine which patients could benefit from treatments that could spare them from unnecessary chemotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 16, 2021 Category: Cancer & Oncology Source Type: news
RadQual signs distribution deal with LEA
Radioisotope manufacturer International Isotope's RadQual nuclear medicine quality-contro...Read more on AuntMinnie.comRelated Reading:
International Isotopes' Q1 revenue declines
International Isotopes revenues slide in 2019
International Isotopes receives FDA nod for I-131
Revenue slips at International Isotopes in Q3
International Isotopes posts Q1 decreases (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 9, 2021 Category: Radiology Source Type: news
SNMMI, Zionexa call out CMS for reimbursement error
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is teaming u...Read more on AuntMinnie.comRelated Reading:
SNMMI urges fast-track review of Technegas for V/Q scans
SNMMI: Imagers should get COVID-19 shots early
SNMMI celebrates 60th anniversary with special issue
New x-ray systems mark Siemens exhibit at RSNA 2020
Imaging agent for breast cancer PET gets FDA nod (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 8, 2021 Category: Radiology Source Type: news
Joint radionuclide therapy-immunotherapy approach effective in prostate cancer model
(Society of Nuclear Medicine and Molecular Imaging) A combination of radionuclide therapy and immunotherapy has proven successful in slowing the progression of prostate cancer and increasing survival time, according to new research published in the February issue of The Journal of Nuclear Medicine. The results of the murine study indicate that radionuclide therapy promotes prostate cancer immunogenicity, provoking a cellular response that makes the tumors more receptive to immunotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 8, 2021 Category: Cancer & Oncology Source Type: news
Lantheus touts ASCO GU talks with PSMA agent
Lantheus Holdings, parent company of Lantheus Medical Imaging, along with it...Read more on AuntMinnie.comRelated Reading:
Lantheus submits drug master file for imaging biomarker
Point Biopharma to use Lantheus' PyL in clinical trial
Lantheus divests Puerto Rico nuclear medicine businesses
FDA clears Lantheus' AI bone software
Sofie, Lantheus ink deal for prostate cancer imaging agent (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 5, 2021 Category: Radiology Source Type: news
